Participating in the Rheumatoid Arthritis M20 Study is a way for patients with rheumatoid arthritis (RA) to contribute to a treatment option. Rheumatoid arthritis is the most common form of autoimmune arthritis. In fact, 1.3 million Americans are affected by this condition. It occurs when the immune system attacks healthy tissue. The tissue targeted will be hit with inflammation, and in the instance of RA, the joints are commonly affected.

RA primarily affects smaller joints in the hands and feet. However, it is capable of affecting organs. Women between the ages of 30 and 50 are the primary demographic with this condition. Rheumatoid arthritis was commonly recognized as a disabling illness, but recent treatments have made living with RA easier.

Rheumatoid arthritis does not have a cure, so most treatment options are targeted toward the symptoms. Fortunately, there are research studies looking at investigational drugs to slow the progression of this condition. Currently, many patients with RA do not respond well to treatment options. The M20 Study is aiming to change that for the better.